John Horton, President, LegitScript
Huffington Post
For cancer patients, what is the “acceptable risk” that a drug will pose safety risks or won’t work properly? That’s one of the thorny questions addressed by the FDA last week in a two-day, open-to-the-public meeting about “biosimilar” drugs — second-generation versions of drugs made from living organisms, or “biologics.”